Teva Pharmaceutical Industries Limited (TEVA) has a consensus analyst rating of Buy, based on 46 analysts covering the stock. Of those, 22 recommend buying, 20 recommend holding, and 4 recommend selling.
The analyst consensus price target for TEVA is $38.33, representing a +20.6% upside from the current price of $31.77. Price targets range from a low of $35.00 to a high of $41.00.
